JP2016512199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512199A5 JP2016512199A5 JP2015561627A JP2015561627A JP2016512199A5 JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5 JP 2015561627 A JP2015561627 A JP 2015561627A JP 2015561627 A JP2015561627 A JP 2015561627A JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- pharmaceutical composition
- cell surface
- surface molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims 11
- 210000004027 cells Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 230000000174 oncolytic Effects 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 102100013077 CD4 Human genes 0.000 claims 1
- 101700022938 CD4 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100005828 CD5 Human genes 0.000 claims 1
- 101700066525 CD5 Proteins 0.000 claims 1
- 102100008191 CD8A Human genes 0.000 claims 1
- 101700054655 CD8A Proteins 0.000 claims 1
- 102100016627 EPHA2 Human genes 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 101710044657 FCGR3B Proteins 0.000 claims 1
- 102100012223 KLRK1 Human genes 0.000 claims 1
- 101710036390 KLRK1 Proteins 0.000 claims 1
- 241000700562 Myxoma virus Species 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100009537 TNFRSF9 Human genes 0.000 claims 1
- 101710040535 TNFRSF9 Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Claims (11)
- 細胞表面分子に特異的な単鎖可変フラグメント（ｓｃＦｖ）と、腫瘍抗原に特異的なｓｃＦｖとを含む二部分分子（ｂｉｐａｒｔｉｔｅ ｍｏｌｅｃｕｌｅ）をコードする、腫瘍溶解性ウイルス。
- 前記細胞表面分子がエフェクター細胞上にある、請求項１記載のウイルス。
- 前記エフェクター細胞がＴリンパ球である、請求項２記載のウイルス。
- 前記腫瘍抗原が、ＥｐｈＡ２、ＨＥＲ２、及びＧＤ２からなる群から選択される、請求項１記載のウイルス。
- 前記細胞表面分子が、ＣＤ３、ＣＤ４、ＣＤ５、ＣＤ８、ＣＤ１６、ＣＤ２８、ＣＤ４０、ＣＤ１３４、ＣＤ１３７、及びＮＫＧ２Ｄからなる群から選択される、請求項１記載のウイルス。
- 前記細胞表面分子がＣＤ３である、請求項１記載のウイルス。
- 前記腫瘍溶解性ウイルスが、ワクシニアウイルス、アデノウイルス、単純ヘルペスウイルス１型（ＨＳＶ１）、粘液腫ウイルス、レオウイルス、ポリオウイルス、水疱性口内炎ウイルス（ＶＳＶ）、麻疹ウイルス（ＭＶ）、又はニューカッスル病ウイルス（ＮＤＶ）である、請求項１記載のウイルス。
- 治療有効量の請求項１記載のウイルスを含有する、個体における癌を治療するための医薬組成物。
- 前記ウイルスの量が、１０５〜１０１３ｐｆｕのウイルスを含む、請求項８記載の医薬組成物。
- 前記個体が、追加の癌治療を必要としている、請求項８記載の医薬組成物。
- 前記追加の癌治療が、手術、放射線、化学療法、免疫療法、ホルモン療法、又はそれらの組合せである、請求項１０記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| PCT/US2014/020935 WO2014138314A1 (en) | 2013-03-05 | 2014-03-05 | Oncolytic virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512199A JP2016512199A (ja) | 2016-04-25 |
| JP2016512199A5 true JP2016512199A5 (ja) | 2017-04-06 |
Family
ID=50424733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561627A Pending JP2016512199A (ja) | 2013-03-05 | 2014-03-05 | 腫瘍溶解性ウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160000842A1 (ja) |
| EP (1) | EP2964241A1 (ja) |
| JP (1) | JP2016512199A (ja) |
| CN (1) | CN105407902A (ja) |
| CA (1) | CA2903096A1 (ja) |
| WO (1) | WO2014138314A1 (ja) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| RS57043B1 (sr) | 2013-10-25 | 2018-05-31 | Psioxus Therapeutics Ltd | Onkolitički adenovirusi snabdeveni heterologus genima |
| WO2016049459A1 (en) * | 2014-09-26 | 2016-03-31 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| CN107406859A (zh) * | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途 |
| BR112017023171A2 (pt) | 2015-04-30 | 2018-07-17 | Psioxus Therapeutics Limited | adenovírus oncolítico que codifica proteína b7 |
| WO2017013419A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| EA201891021A1 (ru) | 2015-12-17 | 2018-11-30 | Псайоксус Терапьютикс Лимитед | Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| SG11201811600PA (en) * | 2016-06-30 | 2019-01-30 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| EP3488005A4 (en) | 2016-07-19 | 2020-07-29 | University of Pittsburgh- Of the Commonwealth System of Higher Education | TARGETING ONCOLYTIC VIRUSES STAT3 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP4273252A3 (en) * | 2016-08-29 | 2024-04-17 | Akamis Bio Limited | Adenovirus armed with bispecific t cell engager (bite) |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| EP3577132A4 (en) * | 2017-02-03 | 2021-03-10 | University of Pittsburgh - of The Commonwealth System of Higher Education | ONCOLYTIC VIRUS THERAPY |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| AU2018258049A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
| GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
| EP3732202A4 (en) | 2017-12-28 | 2022-06-15 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT |
| WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| CN112020510A (zh) | 2018-03-19 | 2020-12-01 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| TW202012440A (zh) * | 2018-04-13 | 2020-04-01 | 瑞士商赫孚孟拉羅股份公司 | 包含4-1bbl之靶向her2的抗原結合分子 |
| WO2019226617A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| WO2020017962A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| JP2021531042A (ja) * | 2018-07-20 | 2021-11-18 | アンサン バイオファーマ, インク.Ansun Biopharma, Inc. | 癌細胞、免疫細胞及び腫瘍微小環境へのシアリダーゼの送達 |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
| EP3958894A1 (en) | 2019-04-25 | 2022-03-02 | DCPrime B.V. | Methods of tumor vaccination |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| EP3957650A1 (en) * | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| CN115161293A (zh) * | 2021-04-01 | 2022-10-11 | 南京惟亚德生物医药有限公司 | 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| IL138857A0 (en) | 1998-04-21 | 2001-10-31 | Micromet Ges For Biomedizinisc | Cd19xcd3 specific polypeptides and uses thereof |
| CA2633713A1 (en) * | 2005-12-21 | 2007-06-28 | Micromet Ag | Epha2 bite molecules and uses thereof |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
-
2014
- 2014-03-05 US US14/770,061 patent/US20160000842A1/en not_active Abandoned
- 2014-03-05 EP EP14714851.4A patent/EP2964241A1/en not_active Ceased
- 2014-03-05 WO PCT/US2014/020935 patent/WO2014138314A1/en active Application Filing
- 2014-03-05 CA CA2903096A patent/CA2903096A1/en not_active Abandoned
- 2014-03-05 CN CN201480025597.3A patent/CN105407902A/zh active Pending
- 2014-03-05 JP JP2015561627A patent/JP2016512199A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512199A5 (ja) | ||
| JP2016514956A5 (ja) | ||
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| JP2019519245A5 (ja) | ||
| HRP20190774T1 (hr) | Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora | |
| Marchini et al. | Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| JP2019513118A5 (ja) | ||
| JP2018512047A5 (ja) | ||
| JP2018527952A5 (ja) | ||
| JP2016505635A5 (ja) | ||
| JP2012136541A5 (ja) | ||
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| JP2019536806A5 (ja) | ||
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| WO2019236633A3 (en) | Cell-based vehicles for potentiation of viral therapy | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| JP2008056679A5 (ja) | ||
| JP2018509163A5 (ja) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| WO2015112805A8 (en) | Human antibodies to pd-l1 | |
| Chulpanova et al. | Recombinant viruses for cancer therapy | |
| JP2016028035A5 (ja) | ||
| JP2018535668A5 (ja) |